Fenofibrate
Fenofibrate is a synthetic lipid-modifying agent in the fibrate class, used clinically to lower elevated triglycerides and, in some settings, to improve mixed dyslipidemia.
Fenofibrate is a synthetic lipid-modifying agent in the fibrate class, used clinically to lower elevated triglycerides and, in some settings, to improve mixed dyslipidemia. It is a prodrug that is converted in vivo to fenofibric acid, the active metabolite. Its principal pharmacologic action is activation of peroxisome proliferator-activated receptor alpha (PPAR-α), which regulates genes involved in fatty acid oxidation, lipoprotein metabolism, and triglyceride clearance.
Beyond its established therapeutic role, fenofibrate continues to be studied in broader biomedical contexts because of its effects on lipid handling, inflammation, and cellular stress pathways. In recent research, it has also appeared in computational drug-repurposing workflows and environmental monitoring studies, reflecting both its clinical relevance and its persistence as a pharmaceutically active compound in the environment.
- Dissolution Enhancement by Binding Agents: A Potential Shortcut to Improving Bioavailability? PMID 42717179
Where the papers sit
9 papers study fenofibrate directly. Those 9 do not group into themes. The set ranges from formulation and assay development to observational safety, pharmacovigilance, disease treatment, and computational drug screening, without a shared biological question or direction. They are no more alike than papers drawn from anywhere in the corpus.
Recent Findings on fenofibrate
Drug Use and Evaluation: Fenofibrate formulation studies target poor solubility and dosage-form performance through polymeric binders, nanoemulsions, and QbD-integrated testing 42717179Sep42260710Jun42093465May. Polymeric binders generally improved dissolution, but poor buffer–tablet correlations favored dissolution testing over solubility screening; NMR also showed drug-specific redistribution during nanoemulsion destabilization 42717179Sep42260710Jun. Isocratic RP-UHPLC-UV and RP-HPLC methods provided rapid, sensitive quality control, while pemafibrate studies assessed safety against a lower-dose selective PPARα modulator 42517867Jul42093465May42379788Jun. Clinical evidence associated fenofibrate with lower sight-threatening diabetic retinopathy risk and improved transplant-free survival in primary biliary cholangitis, although the retinopathy association was absent in South Asians 42702803Sep42214018May. A pregnancy case supported therapeutic plasma exchange followed by fenofibrate for recurrent hypertriglyceridemia-induced pancreatitis, while sepsis models linked fenofibrate to reduced cellular senescence and inflammation through senescence-related genes 42204798May42219284May.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-07-02. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.